Optimizing Vitiligo Treatment: Safety, Efficacy and Special Population Consideration
Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring clinical outcomes and patient-reported measures, with special consideration given to unique challenges in vulnerable populations like children, pregnant women and those with comorbidities, where treatment approaches require careful modification to balance efficacy and safety concerns.
Video content above is prompted by the following:
- How do you assess the safety and effectiveness of vitiligo treatments to determine appropriateness for a patient?
- What clinical and patient-reported outcomes are most important for treatment success?
- How do you approach vitiligo treatment in special populations (eg, children, pregnant women, patients with comorbidities)?
- What unique challenges do these groups present in terms of efficacy, safety and managed care considerations?
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
